Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Ocugen, Inc. (OCGN) Revenue by Segment & Business Profile

Gene therapy product candidates for inherited retinal diseases to healthcare providers was 100.0% of Ocugen, Inc.'s revenue, according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

OCGNOcugen, Inc.Follow OCGN — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
250.8M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
4 Nov, in 11 days

What the company does

Ocugen, Inc. is a biotechnology company in the healthcare sector. Trailing twelve-month revenue: $4.6 million as of 2026-06-30.

Roles we read

from the filings, not the sector label
  • Clinical-stage developer

Ocugen, Inc. — questions

What does Ocugen, Inc. do?
Ocugen, Inc. is a biotechnology company in the healthcare sector. Trailing twelve-month revenue: $4.6 million as of 2026-06-30.
How does Ocugen, Inc. make money?
By the lines it reports in its SEC filings: Gene therapy product candidates for inherited retinal diseases to healthcare providers 100.0% of revenue.

Every figure on this page comes from Ocugen, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.